Vitamin D status has been proposed as relevant to many neurological disorders. Data suggest that vitamin D may be important for the development of the nervous system, and it also plays a role in neuroimmunology and neuroprotection. Lower levels of circulating 25-hydroxyvitamin D have been linked with increased risk of multiple sclerosis (MS) and Alzheimer’s disease (AD). While people with amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), and stroke have lower vitamin D levels than those without the diseases, it is unclear if this is because hypovitaminosis D contributes to disease risk or is a consequence of immobility and other factors caused by the disease. Lower levels of vitamin D have been associated with worse prognosis in MS, PD, ALS, and stroke, while no longitudinal studies have been performed to evaluate such an association in AD. Small pilot trials have been performed to evaluate vitamin D supplementation for some of these diseases, but there have been no phase III studies to support vitamin D supplementation in these patient populations; further, ideal levels of 25-hydroxyvitamin D are not known. Thus, while some expert panels or individuals have suggested routine testing and supplementation for patients with these neurological conditions, it is our opinion that there are currently insufficient data to support high-dose vitamin D supplementation to specifically treat or prevent these conditions.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as •• Of importance
Fernandes de Abreu DA, Eyles D, Féron F. Vitamin D, a neuro-immunomodulator: implications for neurodegenerative and autoimmune diseases. Psycho Neuro Endocrinol. 2009;34(Suppl1):S265–77.
Falkenstein E et al. Multiple actions of steroid hormones—a focus on rapid, nongenomic effects. Pharmacol Rev. 2000;52:513–56.
Khanal R, Nemere I. Membrane receptors for vitamin D metabolites. Crit Rev Eukaryot Gene Expr. 2007;17:31–47.
Burkert R, McGrath J, Eyles D. Vitamin D receptor expression in the embryonic rat brain. Neurosci Res Commun. 2003;33:63–71.
Eyles DW et al. Distribution of the vitamin D receptor and 1α-hydroxylase in human brain. J Chem Neuroanat. 2005;29:21–30.
Tohda C et al. Diosgenin-induced cognitive enhancement in normal mice is mediated by 1,25D3-MARRS. Sci Rep. 2013;5:3395.
Baas D et al. Rat oligodendrocytes express the vitamin D3 receptor and respond to 1,25-dihydroxyvitamin D3. Glia. 2000;31(1):59–68.
Eyles D et al. Vitamin D3 and brain development. Neuroscience. 2003;118:641–53.
Feron F et al. Developmental vitamin D3 deficiency alters the adult rat brain. Brain Res Bull. 2005;65:141–8.
Harms LR et al. Developmental vitamin D deficiency alters adult behaviour in 129/SvJ and C57BL/6 J mice. Behav Brain Res. 2008;187:343–50.
Shirazi HA et al. 1,25-Dihydroxyvitamin D3 enhances neural stem cell proliferation and oligodendrocyte differentiation. Exp Mol Pathol. 2015;98(2):240–5.
Brown J et al. 1,25-Dihydroxyvitamin D3 induces nerve growth factor, promotes neurite outgrowth and inhibits mitosis in embryonic rat hippocampal neurons. Neurosci Lett. 2003;343:139–43.
Latimer CS et al. Vitamin D prevents cognitive decline and enhances hippocampal synaptic function in aging rats. Proc Natl Acad Sci U S A. 2014;111(41):E4359–66.
Landfield PW, Cadwallader-Neal L. Long-term treatment with calcitriol (1,25(OH)2 vit D3) retards a biomarker of hippocampal aging in rats. Neurobiol Aging. 1998;19(5):469–77.
Wang Y et al. Vitamin D3 attenuates cortical infarction induced by middle cerebral arterial ligation in rats. Neuropharmacology. 2000;39(5):873–80.
Balden R, Selvamani A, Sohrabji F. Vitamin D deficiency exacerbates experimental stroke injury and dysregulates ischemia-induced inflammation in adult rats. Endocrinology. 2012;153(5):2420–35.
Brewer LD et al. Vitamin D hormone confers neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons. J Neurosci. 2001;21(1):98–108.
Garcion E et al. 1,25-Dihydroxyvitamin D3 inhibits the expression of inducible nitric oxide synthase in rat central nervous system during experimental allergic encephalomyelitis. Brain Res Mol Brain Res. 1997;45(2):255–67.
Korf H et al. 1,25-Dihydroxyvitamin D3 curtails the inflammatory and T cell stimulatory capacity of macrophages through an IL-10-dependent mechanism. Immunobiology. 2012;217(12):1292–300. This article provided strong evidence for the anti-inflammatory effect of vitamin D on macrophages.
Dursun E, Gezen-AK D, Yilmazer S. A new mechanism for amyloid-b induction of iNOS: vitamin D-VDR pathway disruption. J Alzheimers Dis. 2013;36(3):459–74.
Hur J et al. Regulatory effect of 25-hydroxyvitamin D3 on nitric oxide production in activated microglia. Korean J Physiol Pharmacolx. 2014;18(5):397–402.
Garcion E et al. 1,25-Dihydroxyvitamin D3 regulates the synthesis of gamma-glutamyl transpeptidase and glutathione levels in rat primary astrocytes. J Neurochem. 1999;73(2):859–66.
Shinpo K et al. Effect of 1,25-dihydroxyvitamin D3 on cultured mesencephalic dopaminergic neurons to the combined toxicity caused by L-buthionine sulfoximine and 1-methyl-4-phenylpyridine. J Neurosci Res. 2000;62(3):374–82.
Lu’o’ng KV, Nguyen LT. The beneficial role of vitamin D in Alzheimer’s disease. Am J Alheimers Dis Other Demen. 2011;26(7):511–20.
Durk MR et al. 1,25-Dihydroxyvitamin D3 reduces cerebral amyloid-β accumulation and improves cognition in mouse models of Alzheimer’s disease. J Neurosci. 2014;34(21):7091–101.
Grimm MO et al. Impact of vitamin D on amyloid precursor protein processing and amyloid-β peptid degradation in Alzheimer’s disease. Neurodegener Dis. 2014;13:75–81.
Camu W et al. Vitamin D confers protection to motoneurons and is a prognostic factor of amyotrophic lateral sclerosis. Neurobiol Aging. 2014;35(5):1198–205.
Puchacz E et al. Vitamin D increases expression of the tyrosine hydroxylase gene in adrenal medullary cells. Brain Res Mol Brain Res. 1996;36:193–6.
Sanchez B et al. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum. J Neurosci Res. 2009;87:723–32.
Hollo A, Clemens Z, Lakatos P. Epilepsy and vitamin D. Int J Neurosci. 2014;124(6):387–93.
Di Rosa M et al. Vitamin D3: a helpful immuno-modulator. Immunology. 2011;134:123–39.
Moro JR, Iwata M, von Andriano UH. Vitamin effects on the immune system, vitamins A and D take centre stage. Nat Rev Immunol. 2008;8:685–98.
Ferreira GB et al. 1,25-Dihydroxyvitamin D3 alters murine dendritic cell behaviour in vitro and in vivo. Diabetes Metab Res Rev. 2011;27:933–41.
Farias AS et al. Vitamin D3 induces IDO(+) tolerogenic DCs and enhances treg, reducing the severity of EAE. CNS Neurosci Ther. 2013;19:269–77.
Jeffery LE et al. Availability of 25-hydroxyvitamin D3 to APCs controls the balance between regulatory and inflammatory T cell responses. J Immunol. 2012;189:5155–64.
Lemire JM, Archer DC. 1,25-Dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest. 1991;87:1103–7.
Kang SW et al. 1,25-Dihydroxyvitamin D3 promotes FOXP3 expression via binding to vitamin D response elements in its conserved noncoding sequence region. J Immunol. 2012;188:5276–82. This article provided the first evidence of direct effect of vitamin D on T lymphoctyes.
Chen S et al. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol. 2007;179:1634–47.
Won S et al. Vitamin D prevents hypoxia/reoxygenation-induced blood-brain barrier disruption via vitamin D receptor-mediated NF-kB signaling pathways. PLoS One. 2015;10(3):e0122821.
Grishkan IV et al. 1,25-Dihydroxyvitamin D3 selectively and reversibly impairs T helper-cell CNS localization. Proc Natl Acad Sci U S A. 2013;110(52):21101–6.
Smolders J et al. Expression of vitamin D receptor and metabolizing enzymes in multiple sclerosis-affected brain tissue. J Neuropathol Exp Neurol. 2013;72:91–105.
Wergeland S et al. Dietary vitamin D3 supplements reduce demyelination in the cuprizone model. PLoS One. 2011;6(10):e26262.
Nystad AE et al. Effect of high-dose 1,25-dihydroxyvitamin D3 on remyelination in the cuprizone model. APMIS. 2014;122(12):1178–86.
Hewer S et al. Vitamin D and multiple sclerosis. J Clin Neurosci. 2013;20(5):634–41.
Hayes CE. Vitamin D: a natural inhibitor of multiple sclerosis. Proc Nutr Soc. 2000;59(4):531–5.
Beretich BD, Beretich TM. Explaining multiple sclerosis prevalence by ultraviolet exposure: a geospatial analysis. Mult Scler. 2009;15(8):891–8.
Lucas RM et al. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology. 2011;76(6):520–48.
McDowell TY et al. Sun exposure, vitamin D, and age at disease onset in relapsing multiple sclerosis. Neuroepidemiology. 2011;36(1):39–45.
Kampman MT, Brustad M. Vitamin D: a candidate for the environmental effect in multiple sclerosis—observations from Norway. Neuroepidemiology. 2008;30(3):140–6.
Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology. 2008;71(2):129–35.
Duan S et al. Vitamin D status and the risk of multiple sclerosis: a systemic review and meta-analysis. Neurosci Lett. 2014;570:108–13.
Munger KL et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006;296(23):2832–8.
Mowry EM et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol. 2010;67(5):618–24.
Runia TF et al. Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology. 2012;79(3):261–6.
Simpson S et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol. 2010;68(2):193.203.
Van der Mei IA et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmani. Aust J Neurol. 2007;254(5):581–90.
Smolders J et al. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler. 2008;14(9):1220–4.
Mowry EM et al. Vitamin D status predicts new brain MRI activity in multiple sclerosis. Ann Neurol. 2012;72(2):234–40. This study demonstrated that serum vitamin D levels are inversely associated with the development of new T2-weighted lesions on MRI in patients with MS.
Weinstock-Guttman B et al. Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients. J Neurol Neurosurg Psychiatry. 2011;82(2):189–95.
Stewart N et al. Interferon- β and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS. Neurology. 2012;79(3):254–60.
Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis. Lancet Neurol. 2010;9(6):599–612.
Ganesh A et al. The case for vitamin D supplementation in multiple sclerosis. Mult Scler Relat Disord. 2013;2(4):281–306.
Burton JM et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology. 2010;74(23):1852–9.
Soilu-Hanninen M et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012;83(5):565–71. This double-blind, placebo-controlled, randomized study demonstrated that patients with MS receiving vitamin D supplementation had fewer new T2-weighted lesions and a significantly lower number of T1 enhancing lesions as well as a tendency for reduced disability accumulation and improved timed tandem walk compared to controls not receiving vitamin D supplementation.
Wingerchuk DM et al. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2005;76(9):1294–6.
Pierrot-Deseilligny C et al. Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation. Ther Adv Neurol Disord. 2012;5(4):187–98.
James E et al. The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis. Mult Scler. 2013;19(12):1571–9.
Mosayebi G et al. Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunol Investig. 2011;40(6):627–39.
Stein MS et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology. 2011;77(17):1611–8.
Kampman MT et al. Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Mult Scler. 2012;18(8):1144–51.
Shaygannejad V et al. Effects of adjunct low-dose vitamin D on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Mult Scler Int. 2012;2012:452541.
Pozuelo-Moyano B et al. A systematic review of randomized, double-blind, placebo-controlled trials examining the clinical efficacy of vitamin D in multiple sclerosis. Neuroepidemiology. 2013;40(3):147–53.
Mowry EM. Vitamin D: evidence for its role as a prognostic factor in multiple sclerosis. J Neurol Sci. 2011;311(1-2):19–22.
Slinin Y et al. 25-Hydroxyvitamin D levels and cognitive performance and decline in elderly men. Neurology. 2010;74:33–41.
Annweiler C et al. Hypovitaminosis D and executive dysfunction in older adults with memory complaint: a memory clinic-based study. Dement Geriatr Cogn Disord. 2013;37:286–93.
Brouwer-Brolsma EM et al. Serum 25-hydroxyvitamin D is associated with cognitive executive function in Dutch prefrail and frail elderly: a cross-sectional study exploring the associations of 25-hydroxyvitamin D with glucose metabolism, cognitive performance and depression. J Am Med Dir Assoc. 2013;14(852):e859–817.
Annweiler C et al. Serum vitamin D deficiency as a predictor of incident non-Alzheimer dementias: a 7-year longitudinal study. Dement Geriatr Cogn Disord. 2011;32:273–8.
Balion C et al. Vitamin D, cognition, and dementia: a systematic review and meta-analysis. Neurology. 2012;79:1397–405.
Annweiler C, Llewellyn DJ, Beauchet O. Low serum vitamin D concentrations in Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis. 2013;33:659–74.
Chei CL et al. Vitamin D levels and cognition in elderly adults in China. J Am Geriatr Soc. 2014;62:2125–9.
Littlejohns TJ et al. Vitamin D and the risk of dementia and Alzheimer disease. Neurology. 2014;83:920–8. This large prospective cohort study showed that hypovitaminosis D resulted in a markedly increased risk of incident Alzheimer’s disease and all-cause dementia.
Berridge MJ. Calcium regulation of neural rhythms, memory and Alzheimer's disease. J Physiol. 2014;592:281–93.
Moon M et al. Vitamin D-binding protein interacts with Abeta and suppresses Abeta-mediated pathology. Cell Death Differ. 2013;20:630–8.
Morley JE, Farr SA. The role of amyloid-beta in the regulation of memory. Biochem Pharmacol. 2014;88:479–85.
Bishnoi RJ, Palmer RF, Royall DR. Vitamin D binding protein as a serum biomarker of Alzheimer's disease. J Alzheimers Dis. 2015;43:37–45.
Johansson P et al. Cerebrospinal fluid (CSF) 25-hydroxyvitamin D concentration and CSF acetylcholinesterase activity are reduced in patients with Alzheimer's disease. PLoS One. 2013;8:e81989.
Muenchhoff J et al. Plasma protein profiling of mild cognitive impairment and Alzheimer's disease across two independent cohorts. J Alzheimers Dis. 2015;43:1355–73.
Laczmanski L et al. Vitamin D receptor gene polymorphisms in Alzheimer's disease patients. Exp Gerontol. 2015;69:142–7.
Annweiler C et al. Cognitive effects of vitamin D supplementation in older outpatients visiting a memory clinic: a pre-post study. J Am Geriatr Soc. 2012;60:793–5.
Stein MS et al. A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer's disease. J Alzheimers Dis. 2011;26:477–84.
Przybelski R et al. Rapid correction of low vitamin D status in nursing home residents. Osteoporos Int. 2008;19:1621–8.
Annweiler C et al. ‘Vitamin D and cognition in older adults’: updated international recommendations. J Intern Med. 2014;277:45–57.
Ding H et al. Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology. 2013;81:1531–7.
Peterson AL, Mancini M, Horak FB. The relationship between balance control and vitamin D in Parkinson's disease—a pilot study. Mov Disord. 2013;28:1133–7.
Evatt ML et al. Prevalence of vitamin d insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol. 2008;65:1348–52.
Suzuki M et al. 25-Hydroxyvitamin D, vitamin D receptor gene polymorphisms, and severity of Parkinson's disease. Mov Disord. 2012;27:264–71.
Sato Y, Honda Y, Iwamoto J. Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurology. 2007;68:911–5.
Smith MP et al. Calcitriol protection against dopamine loss induced by intracerebroventricular administration of 6-hydroxydopamine. Neurochem Res. 2006;31:533–9.
Kim JS et al. 1alpha,25-Dihydroxyvitamin D(3) Protects dopaminergic neurons in rodent models of Parkinson’s disease through inhibition of microglial activation. J Clin Neurol. 2006;2:252–7.
Wang JY et al. Vitamin D(3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats. Brain Res. 2001;904:67–75.
Butler MW et al. Vitamin D receptor gene as a candidate gene for Parkinson disease. Ann Hum Genet. 2011;75:201–10.
Torok R et al. Association of vitamin D receptor gene polymorphisms and Parkinson's disease in Hungarians. Neurosci Lett. 2013;551:70–4.
Lee YH, Kim JH, Song GG. Vitamin D receptor polymorphisms and susceptibility to Parkinson's disease and Alzheimer's disease: a meta-analysis. Neurol Sci. 2014;35:1947–53.
Zhang ZT et al. Association between vitamin D receptor gene polymorphisms and susceptibility to Parkinson's disease: a meta-analysis. Neurosci Lett. 2014;578:122–7.
Camu W et al. Vitamin D confers protection to motoneurons and is a prognostic factor of amyotrophic lateral sclerosis. Neurobiol Aging. 2014;35:1198–205. This study showed that lower levels of vitamin D correlated with faster functional decline in ALS patients, even after excluding non-ambulatory patients.
Blasco H et al. Vitamin D is not a protective factor in ALS. CNS Neurosci Ther. 2015;21(8):651–6.
Karam C et al. Vitamin D deficiency and its supplementation in patients with amyotrophic lateral sclerosis. J Clin Neurosci. 2013;20:1550–3.
Wang L et al. Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies. Circ Cardiovasc Qual Outcomes. 2012;5:819–29.
Schneider AL et al. Vitamin D, vitamin D binding protein gene polymorphisms, race and risk of incident stroke: the Atherosclerosis Risk in Communities (ARIC) study. Eur J Neurol. 2015;22:1220–7.
Brondum-Jacobsen P et al. 25-Hydroxyvitamin D and symptomatic ischemic stroke: an original study and meta-analysis. Ann Neurol. 2013;73:38–47.
Chowdhury R et al. Circulating vitamin D, calcium and risk of cerebrovascular disease: a systematic review and meta-analysis. Eur J Epidemiol. 2012;27:581–91.
Welles CC et al. Vitamin D deficiency and cardiovascular events in patients with coronary heart disease: data from the heart and soul Study. Am J Epidemiol. 2014;179:1279–87.
Herrmann M et al. Serum 25-hydroxyvitamin D: a predictor of macrovascular and microvascular complications in patients with type 2 diabetes. Diabetes Care. 2015;38:521–8.
Chung PW et al. 25-Hydroxyvitamin D status is associated with chronic cerebral small vessel disease. Stroke. 2015;46:248–51.
Michos ED et al. Vitamin D and subclinical cerebrovascular disease: the atherosclerosis risk in communities brain magnetic resonance imaging study. JAMA Neurol. 2014;71:863–71.
Yalbuzdag SA et al. Is 25(OH)D associated with cognitive impairment and functional improvement in stroke? A retrospective clinical study. J Stroke Cerebrovasc Dis. 2015;24:1479–86.
Han B et al. Low serum levels of vitamin D are associated with post-stroke depression. Eur J Neurol. 2015;22(9):1269–74.
Turetsky A, Goddeau Jr RP, Henninger N. Low serum vitamin D is independently associated with larger lesion volumes after ischemic stroke. J Stroke Cerebrovasc Dis. 2015;24:1555–63.
Daubail B et al. Association between serum concentration of vitamin D and 1-year mortality in stroke patients. Cerebrovasc Dis. 2014;37:364–7.
Compliance with Ethical Standards
Conflict of Interest
Anusha K. Yeshokumar and Deanna Saylor declare that they have no conflict of interest.
Michael D. Kornberg reports grants from NINDS and from National Multiple Sclerosis Society-American Academy of Neurology.
Ellen M. Mowry reports grants from Biogen Idec and received free medication for a clinical trial from Teva Neuroscience, and Dr. Mowry is PI of a multicenter randomized controlled trial of vitamin D supplementation in people with MS (sponsored by the National MS Society). She is site PI for a clinical trial sponsored by Sun Pharma.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
This article is part of the Topical Collection on Neurologic Manifestations of Systemic Disease
About this article
Cite this article
Yeshokumar, A.K., Saylor, D., Kornberg, M.D. et al. Evidence for the Importance of Vitamin D Status in Neurologic Conditions. Curr Treat Options Neurol 17, 51 (2015). https://doi.org/10.1007/s11940-015-0380-3
- Vitamin D
- Central nervous system
- Multiple sclerosis
- Alzheimer’s disease
- Parkinson’s disease
- Amyotrophic lateral sclerosis